Low Libido: Drugs That Cause It and Drugs That Treat It

Why Medications Are a Leading Cause of Low Libido

Prescription drugs rank among the most underrecognized reasons for diminished sexual desire. A 2022 meta-analysis in the Journal of Sexual Medicine estimated that medication-induced sexual dysfunction accounts for roughly 25% of all cases presenting to sexual health clinics [5]. The mechanism varies by drug class. SSRIs increase serotonin signaling in pathways that actively inhibit dopamine and norepinephrine, both of which are required for normal arousal and desire. Antihypertensives may lower pelvic blood flow or dampen sympathetic nervous system tone. Antiandrogens and 5-alpha reductase inhibitors directly reduce circulating androgens.

A practical problem compounds the pharmacologic one: clinicians frequently fail to ask about sexual side effects, and patients rarely volunteer the information. One cross-sectional study of 1,101 adults on chronic medications found that only 14% had been asked about sexual function by their prescriber in the prior year [6]. That gap means many people attribute their low libido to stress, aging, or relationship issues when a simple medication change could resolve it.

Antidepressants: The Most Common Offenders

SSRIs and SNRIs are responsible for the largest share of drug-induced libido loss. A prospective study published in the Journal of Clinical Psychiatry (N=1,022) found that 73% of patients on SSRIs reported sexual dysfunction, with decreased desire being the most frequent complaint at 58% [1]. Paroxetine and fluvoxamine tend to produce the highest rates. Sertraline and escitalopram fall in the middle. Venlafaxine and duloxetine (SNRIs) carry similar risk.

Bupropion stands apart. Because it acts on dopamine and norepinephrine rather than serotonin, sexual side effect rates in head-to-head trials are comparable to placebo [4]. The STAR*D trial data confirmed that switching from an SSRI to bupropion improved sexual function scores in a majority of patients who had reported SSRI-related sexual problems [7].

Mirtazapine is another option with lower sexual side effect rates, though sedation and weight gain may limit its appeal. Vilazodone and vortioxetine, newer serotonergic agents, appear to carry a somewhat lower risk than traditional SSRIs based on pooled trial data, but the evidence is less mature [8].

For patients who cannot switch antidepressants, adding bupropion 150 mg to the existing SSRI regimen has shown benefit. A randomized controlled trial (N=218) in the American Journal of Psychiatry found that adjunctive bupropion SR significantly improved desire and arousal compared with placebo over 6 weeks [4].

Blood Pressure Medications and Cardiac Drugs

Beta-blockers, particularly older non-selective agents like propranolol, have long been associated with reduced libido and erectile difficulty. A meta-analysis of 15 randomized trials (N=35,000+) found that beta-blockers increased the risk of reported sexual dysfunction by approximately 22% relative to placebo [9]. Newer cardioselective agents like nebivolol may carry a lower risk. Nebivolol's nitric oxide-potentiating properties appear to preserve or even improve sexual function in some studies.

Thiazide diuretics are also implicated. The TOMHS trial, which randomized 902 men and women to five different antihypertensive classes, reported that chlorthalidone was associated with the highest incidence of sexual problems at 24 months [10].

ACE inhibitors and ARBs are generally considered the most libido-neutral antihypertensives. The Endocrine Society's 2018 guideline on testosterone therapy notes that switching from a beta-blocker to an ACE inhibitor or ARB should be considered as a first step in men presenting with both hypertension and low desire [11].

Spironolactone, used for heart failure and resistant hypertension, is an androgen receptor antagonist. It predictably lowers libido in men and can contribute to desire problems in women at higher doses. Eplerenone, a more selective mineralocorticoid receptor antagonist, does not carry the same antiandrogenic profile.

Hormonal Medications and Antiandrogens

Oral contraceptives increase sex hormone-binding globulin (SHBG), which binds free testosterone and can reduce desire. A Cochrane review examined 36 trials of hormonal contraceptives and found that while most women reported no change, a consistent subgroup of 15 to 20% reported decreased libido [12]. The effect appears more pronounced with pills containing higher-dose ethinyl estradiol and antiandrogenic progestins like drospirenone or cyproterone acetate.

5-alpha reductase inhibitors (finasteride, dutasteride), prescribed for benign prostatic hyperplasia and androgenetic alopecia, block conversion of testosterone to dihydrotestosterone. Sexual side effects including decreased libido occurred in 3.4 to 15.8% of men in clinical trials, depending on the study [13]. A vocal patient community has reported persistent sexual dysfunction after discontinuation, a contested condition sometimes called post-finasteride syndrome.

GnRH agonists and antagonists (leuprolide, degarelix), used in prostate cancer and endometriosis, suppress gonadal steroid production almost completely. Loss of libido is expected in nearly all patients and is considered a direct pharmacologic consequence rather than a side effect.

Opioids, Gabapentinoids, and Other CNS Drugs

Chronic opioid therapy induces hypogonadism in 21 to 86% of patients, depending on dose and formulation [14]. The mechanism involves direct suppression of the hypothalamic-pituitary-gonadal axis. Dr. Andrea Rubinstein, writing in the Journal of Clinical Endocrinology & Metabolism, stated: "Opioid-induced androgen deficiency is one of the most clinically significant and undertreated endocrine consequences of long-term opioid use" [14].

Gabapentin and pregabalin have both been linked to decreased libido in post-marketing surveillance data, though the incidence in clinical trials was low (1 to 6%). Benzodiazepines can suppress desire through CNS depression, and antipsychotics, particularly those that raise prolactin (risperidone, paliperidone, haloperidol), frequently cause sexual dysfunction. A cross-sectional study of 636 patients on antipsychotics found that 50.3% reported sexual dysfunction, with prolactin-raising agents showing significantly higher rates than prolactin-sparing drugs like aripiprazole and quetiapine [15].

Testosterone Replacement: First-Line for Hypogonadal Men

For men with confirmed low testosterone (<300 ng/dL on two morning samples) and symptoms of low desire, testosterone replacement therapy (TRT) is the primary pharmacologic intervention. The TRAVERSE trial (N=5,246), the largest randomized testosterone trial completed to date, confirmed that testosterone gel improved sexual desire scores significantly compared with placebo over 22 months, with a mean difference of 0.49 points on the Psychosexual Daily Questionnaire desire domain (P<0.001) [16].

The Endocrine Society's 2018 clinical practice guideline recommends testosterone therapy for men with "unequivocally low serum testosterone concentrations and clinical symptoms" [11]. It explicitly states that testosterone should not be prescribed to men with normal levels solely for sexual complaints.

Available formulations include topical gels (AndroGel, Testim), intramuscular injections (testosterone cypionate, enanthate), subcutaneous pellets, nasal gel (Natesto), and oral testosterone undecanoate (Jatenzo). Topical gels provide the most physiologic delivery, mimicking the natural diurnal testosterone pattern.

In women, the evidence base is narrower but growing. A Lancet Diabetes & Endocrinology systematic review and meta-analysis of 46 RCTs (N=8,480) found that transdermal testosterone significantly increased satisfying sexual events, desire, and arousal in postmenopausal women, with a standardized mean difference for desire of 0.36 (95% CI 0.22 to 0.50) [17]. Dr. Susan Davis, lead author of the International Society for Sexual Medicine's position statement, wrote: "Global data now support the use of testosterone therapy at physiological doses for postmenopausal women with HSDD who do not respond to non-pharmacologic interventions" [17]. No testosterone product is currently FDA-approved for women, making this an off-label use.

Flibanserin (Addyi): A Nightly Central-Acting Agent

Flibanserin was FDA-approved in 2015 for premenopausal women with acquired, generalized HSDD. It acts as a 5-HT1A agonist and 5-HT2A antagonist, rebalancing serotonin-dopamine-norepinephrine signaling in brain circuits involved in desire. Three key trials (VIOLET, DAISY, BEGONIA; combined N=2,400+) demonstrated a statistically significant increase in satisfying sexual events (SSEs) of approximately 0.5 to 1.0 additional events per month over placebo, alongside meaningful improvements in desire measured by the Female Sexual Function Index [18].

The drug must be taken nightly, and alcohol must be avoided due to a risk of severe hypotension and syncope. This boxed warning has limited uptake. Common side effects include dizziness, somnolence, and nausea, which tend to diminish after the first two weeks. Flibanserin is not approved for postmenopausal women, though the SNOWDROP trial showed efficacy in that population as well.

Bremelanotide (Vyleesi): On-Demand Option

Bremelanotide, a melanocortin-4 receptor agonist, received FDA approval in 2019 for premenopausal HSDD. Unlike flibanserin, it is administered as a subcutaneous injection at least 45 minutes before anticipated sexual activity. The RECONNECT trials (two Phase 3 studies, combined N=1,247) showed that bremelanotide increased desire scores by 0.61 points on the Female Sexual Distress Scale-Desire/Arousal/Orgasm compared with a 0.21-point change for placebo (P<0.0001) [19].

Nausea is the most common adverse event, affecting roughly 40% of patients with the first dose but declining to about 2% by the eighth dose. The FDA label limits use to no more than one injection per 24 hours and no more than 8 injections per month. Bremelanotide is not recommended for patients with uncontrolled hypertension, as it can transiently raise blood pressure by 6 to 12 mmHg.

Practical Approach: Deprescribing Before Prescribing

The most effective pharmacologic strategy for drug-induced low libido is often removal or substitution of the offending agent, not addition of a new one. A 2019 British Medical Journal Best Practice review recommended a stepwise approach: (1) confirm the temporal relationship between medication initiation and libido decline, (2) trial a dose reduction if clinically safe, (3) switch to a within-class alternative with a lower sexual side effect profile, and (4) add a mitigating agent only if steps 1 through 3 are insufficient [20].

For SSRI-induced desire loss specifically, the options with best evidence are switching to bupropion, adding bupropion as adjunct, or switching to a low-sexual-side-effect antidepressant like mirtazapine or vortioxetine. A "drug holiday" (skipping SSRI doses on weekends) has been studied for sertraline and paroxetine with mixed results and carries a risk of discontinuation symptoms and mood destabilization. Most guidelines do not recommend it.

For beta-blocker-induced problems, switching to nebivolol or to an ACE inhibitor or ARB is the standard recommendation. For spironolactone-induced issues, switching to eplerenone addresses the antiandrogenic mechanism directly.

PDE5 inhibitors (sildenafil, tadalafil) treat erectile dysfunction but do not directly increase desire. They may improve the overall sexual experience enough to create positive reinforcement that secondarily boosts interest, but they should not be considered libido treatments per se.

Emerging Pharmacologic Targets

Several investigational compounds are in clinical development for HSDD. Epelsiban, an oxytocin receptor antagonist, showed mixed results in early trials. S-equol, a selective estrogen receptor beta agonist derived from soy metabolism, has entered Phase 2 studies for menopausal sexual dysfunction. Kisspeptin, a neuropeptide that sits upstream of the HPG axis, has demonstrated ability to increase sexual brain processing in fMRI studies of women with HSDD (N=32), but no large clinical trial has been completed [21].

The pipeline reflects growing recognition that desire is regulated by multiple overlapping neurobiological systems. Dopaminergic, melanocortinergic, oxytocinergic, and peptidergic pathways all contribute, which is why no single drug works for everyone.